Table 1.
Clinical trial characteristics *.
| Author, Year | State(s) | Trial ID | Phase(s) | Total n |
|---|---|---|---|---|
| Aggarwal 2019 | PA | NCT02163057 | I/IIa | 22 |
| Anderson 2015 | MD, NY, OR | NCT01342978 | NR | 116 |
| Ang 2010 | TX | NCT00047008 | III | 206 |
| Chen 2017 | CA | NCT02048020/NCT01716195 | II | 44 |
| Chera 2015 | NC, FL | NCT01530997 | II | 44 |
| Chera 2019 | NC | NCT02281955 | II | 114 |
| Chera 2020 | NC, FL | NCT03077243 | II | 115 |
| Ding 2015 | TX | NCT01893307 | II/III | 31 |
| Dunn 2018 | NY | NCT01721525 | Ib | 10 |
| Fakhry 2008 | MD | ECOG protocol 2399 | II | 38 |
| Fakhry 2014 | MD | RTOG0129/RTOG0522 | III | 105 |
| Foster 2020 | IL | NCT02258659 | II | 62 |
| Gillison 2019 | TX | NCT01302834 | NR | 805 |
| Kumar 2008 | MI | UMCC9921 | NR | 50 |
| Ma 2019 | MN, AZ, FL | NCT01932697 | II | 79 |
| Marur 2016 | CT | NCT01084083 | II | 80 |
| Massarelli 2019 | TX | NCT02426892 | II | 22 |
| Miles 2021 | NY | NCT02072148 | II | 54 |
| Misiukiewicz 2019 | NY | NCT01706939 | III | 23 |
| Mowery 2020 | NC | NCT01908504 | NR | 62 |
| Oppelt 2021 | MO | NCT02101034 | II | 24 |
| Rosenberg 2021 | IL | NCT02258659 | II | 90 |
| Rosenthal 2016 | TX | NCT00004227 | III | 75 |
| Samuels 2016 | MI | PO1CA59827 | II | 53 |
| Seiwert 2019 | IL | NCT01816984 | II | 62 |
| Settle 2009 | MD | TAX 324 | III | 68 |
| Shaverdian 2019 | CA | NCT01716195 | II | 24 |
| Spector 2012 | MI | UCMCC02-021 | II | 78 |
| Swiecicki 2020 | MI | NCT01663259/NCT00904345 | II | 42 |
| Swisher-McClure 2020 | PA | NCT02159703 | II | 60 |
| Voskens 2012 | MD | NCT00257738 | I | 31 |
| Yom 2021 | CA | NCT02254278 | II | 306 |
NR = Not reported. * All trials were classified as Level 1 according to the OCEBM LOE.